Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 18/20 | 0.82 |
| ▸ | IGF1R | P08069 | 18/20 | 0.82 |
| ▸ | ERBB3 | P21860 | 18/20 | 0.82 |
| ▸ | ERBB4 | Q15303 | 18/20 | 0.82 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | TEK | Q02763 | 1/20 | 0.67 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6432234 | 1.00 | EGFR (0.82) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL14268421 | 0.92 | IGF1R (0.75) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6431510 | 0.92 | EGFR (0.83) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6431506 | 0.92 | EGFR (0.83) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL4820363 | 0.90 | EGFR (0.81) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL4820379 | 0.90 | EGFR (0.81) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6431591 | 0.90 | EGFR (1.00) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6430512 | 0.90 | EGFR (1.00) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6430510 | 0.90 | EGFR (1.00) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6433545 | 0.90 | EGFR (1.00) | EGFRERBB2IGF1RERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | EGFR 2229/4885ERBB2 529/4885IGF1R 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.